Article info

Download PDFPDF

Comment on ‘Sustained discontinuation of infliximab with a raising-dose strategy after obtaining remission in patients with rheumatoid arthritis: the RRRR study, a randomised controlled trial’ by Tanaka et al
Free

Authors

  1. Correspondence to Dr Theo Rispens, Immunopathology, Sanquin Research, Amsterdam, The Netherlands; t.rispens{at}sanquin.nl
View Full Text

Citation

Berkhout LC, l'Ami MJ, Wolbink GJ, et al
Comment on ‘Sustained discontinuation of infliximab with a raising-dose strategy after obtaining remission in patients with rheumatoid arthritis: the RRRR study, a randomised controlled trial’ by Tanaka et al

Publication history

  • Received October 29, 2019
  • Accepted November 1, 2019
  • First published November 19, 2019.
Online issue publication 
October 12, 2021

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.